# A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke

> **NCT07754825** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** LT3001 Drug:high dose
- **DRUG:** LT3001 Drug: low dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07754825
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07754825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07754825, "A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07754825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*